AKT1 and neoplasm: RXDX-106 has been characterized in colorectal and breast cancer models and has been shown to impair Axl, Tyro3, MerTK, Akt, and Erk phosphorylation; tumor growth in vivo; and infiltration of leukocytes, macrophages, NK cells, and CD8+ T cells [141].